![Pharmaceuticals | Free Full-Text | In Vitro Antiviral Activity of Tyrosinase from Mushroom Agaricus bisporus against Hepatitis C Virus | HTML Pharmaceuticals | Free Full-Text | In Vitro Antiviral Activity of Tyrosinase from Mushroom Agaricus bisporus against Hepatitis C Virus | HTML](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-14-00759/article_deploy/html/images/pharmaceuticals-14-00759-g001-550.jpg)
Pharmaceuticals | Free Full-Text | In Vitro Antiviral Activity of Tyrosinase from Mushroom Agaricus bisporus against Hepatitis C Virus | HTML
![C-SWIFT: GRAZOPREVIR/ELBASVIR + SOFOSBUVIR IN CIRRHOTIC AND NONCIRRHOTIC, TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION, FOR DURATIONS OF 4, 6 OR 8 WEEKS AND GENOTYPE 3 INFECTION FOR DURATIONS OF 8 OR 12 WEEKS C-SWIFT: GRAZOPREVIR/ELBASVIR + SOFOSBUVIR IN CIRRHOTIC AND NONCIRRHOTIC, TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION, FOR DURATIONS OF 4, 6 OR 8 WEEKS AND GENOTYPE 3 INFECTION FOR DURATIONS OF 8 OR 12 WEEKS](https://www.natap.org/2015/images/042315/042315-7/EASL3.gif)
C-SWIFT: GRAZOPREVIR/ELBASVIR + SOFOSBUVIR IN CIRRHOTIC AND NONCIRRHOTIC, TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION, FOR DURATIONS OF 4, 6 OR 8 WEEKS AND GENOTYPE 3 INFECTION FOR DURATIONS OF 8 OR 12 WEEKS
![Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells | bioRxiv Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2020/09/18/2020.09.18.302398/F3.large.jpg)
Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells | bioRxiv
![Zepatier for the Treatment of Chronic Hepatitis C Genotype 1 and 4 Infection - Clinical Trials Arena Zepatier for the Treatment of Chronic Hepatitis C Genotype 1 and 4 Infection - Clinical Trials Arena](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-108-800x418.jpg)
Zepatier for the Treatment of Chronic Hepatitis C Genotype 1 and 4 Infection - Clinical Trials Arena
![Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction. - Abstract - Europe PMC Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5490957/bin/jtim-05-008-g001.jpg)
Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction. - Abstract - Europe PMC
![Classification of direct-acting antivirals (DAAs) according to their... | Download Scientific Diagram Classification of direct-acting antivirals (DAAs) according to their... | Download Scientific Diagram](https://www.researchgate.net/publication/348469862/figure/tbl2/AS:979958105124864@1610651627869/Classification-of-direct-acting-antivirals-DAAs-according-to-their-mechanism-of-action.png)
Classification of direct-acting antivirals (DAAs) according to their... | Download Scientific Diagram
Full article: Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C
![Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent - ScienceDirect Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0168827815002913-gr1.jpg)
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent - ScienceDirect
![Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir | Scientific Reports Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-020-73641-9/MediaObjects/41598_2020_73641_Fig1_HTML.png)
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir | Scientific Reports
![Viruses | Free Full-Text | Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals | HTML Viruses | Free Full-Text | Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals | HTML](https://www.mdpi.com/viruses/viruses-07-02968/article_deploy/html/images/viruses-07-02968-g001.png)
Viruses | Free Full-Text | Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals | HTML
![Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent - Journal of Hepatology Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent - Journal of Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e85f861c-8d18-4236-a1c5-91dcb64c3b0d/fx1_lrg.jpg)